April 8, 2026
Incyclix Bio
Incyclix Bio develops small molecule inhibitors of CDKs for...
- Round
- Series B
- Amount raised
- $5M
- Lead investor
- Boxer Capital
- Industry
- Biotechnology
- Headquarters
- Durham, United States
- Employees
- 11-50
- Website
- incyclixbio.com
- —
Other investors
- Eshelman Ventures